Cipla Limited has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) on 10th April 2023 to manufacture and market Galvus and Galvus combination brands, used in the treatment of type 2 diabetes from 1st January 2026.
Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category. It inhibits the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas.
As per Cipla, Galvus has the potential to contribute significantly to its portfolio in the diabetes care continuum space with reported sales of INR 268 Cr as per IQVIA MAT February 2023.
The agreement is subject to satisfaction of certain conditions precedent. During the interim period we would continue to market and distribute Galvus branded products.
The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/ metformin (Eucreas by Novartis) as an oral treatment for type-2 diabetes.
